Weight Loss With Subcutaneous Semaglutide Versus Other Glucagon Like Peptide-1 Receptor Agonists In Type 2 Diabetes: A Systematic Review.

Abstract

GLP-1 receptor agonists (GLP-1 RAreduce elevated blood glucose levels and induce weight loss. Multiple GLP-1 RAs and one combined GLP-1/GIP agonist currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes(T2DM), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO, and was conducted in accordance with the PRISMA and MOOSE guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide, and tirzepatide. In the identified studies multiple dosing regimens were utilised for semaglutide. Randomised trials support superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2DM, but tirzepatide is more effective than semaglutide. There is evidence that semaglutide is superior to other GLP-1RAs for inducing weight loss in T2DM, but is less effective than tirzepatide. This article is protected by copyright. All rights reserved.